Deficiency of Prdm13, a Dorsomedial Hypothalamus-Enriched Gene
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Regulation of the Gastrin Promoter by Epidermal Growth Factor and Neuropeptides JUANITA M
Proc. Nati. Acad. Sci. USA Vol. 86, pp. 3036-3040, May 1989 Biochemistry Regulation of the gastrin promoter by epidermal growth factor and neuropeptides JUANITA M. GODLEY AND STEPHEN J. BRAND Gastrointestinal Unit, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114 Communicated by Kurt J. Isselbacher, December 30, 1988 ABSTRACT The regulation of gastrin gene transcription gastrin secretion (12, 13), the effect of GRP on gastrin gene was studied in GH4 pituitary cells transfected with constructs expression has not been reported. Antral G cells are also comprised of the first exon of the human gastrin gene and inhibited by the paracrine release of somatostatin from various lengths of 5' regulatory sequences ligated upstream of adjacent antral D cells (14), and local release of somatostatin the reporter gene chloramphenicol acetyltransferase. Gastrin inhibits gastrin gene expression as well as gastrin secretion reporter gene activity in GH4 cells was equal to the activity of (15). a reporter gene transcribed from the endogenously expressed In contrast to the detailed studies on gastrin secretion, the growth hormone promoter. The effect of a variety of peptides regulation of gastrin gene expression has not been well on gastrin gene transcription including epidermal growth investigated. The cellular mechanisms controlling gastrin factor (normally present in the gastric lumen), gastrin- secretion have been analyzed using isolated primary G cells releasing peptide, vasoactive intestinal peptide, and somato- (12, 13); however, the limited viability of these cells has statin (present in gastric nerves) was assessed. Epidermal precluded their use in studying the regulation of gastrin gene growth factor increased the rate ofgastrin transcription almost transcription using DNA transfection techniques. -
Adrenocorticotrophic and Melanocyte-Stimulating Peptides in the Human Pituitary by ALEXANDER P
Biochem. J. (1974) 139, 593-602 593 Printed in Great Britain Adrenocorticotrophic and Melanocyte-Stimulating Peptides in the Human Pituitary By ALEXANDER P. SCOTT and PHILIP J. LOWRY* Department ofChemical Pathology, St. Bartholomew's Hospital, London EC1A 7BE, U.K. and CIBA Laboratories, Horsham, Sussex RH12 4AB, U.K. (Received 7 December 1973) The adrenocorticotrophic and melanocyte-stimulating peptides of the human pituitary were investigated by means of radioimmunoassay, bioassay and physicochemical pro- cedures. Substantial amounts of adrenocorticotrophin and a peptide resembling /8-lipotrophin were identified in pituitary extracts, but a-melanocyte-stimulating hormone, ,B-melanocyte-stimulating hormone and corticotrophin-like intermediate lobe peptide, which have been identified in thepars intermedia ofpituitaries from other vertebrates, were not found. The absence of fJ-melanocyte-stimulating hormone appears to contradict previous chemical and radioimmunological studies. Our results suggest, however, that it is not a natural pituitary peptide but an artefact formed by enzymic degradation of ,6-lipotrophin during extraction. Melanocyte-stimulating and corticotrophic pep- extraction of human pituitaries for growth hormone tides have been identified in the pituitaries of all (Dixon, 1960). Its stucture was determined by Harris vertebrate species studied, and several have been (1959) and shown to be similar to ,B-MSH isolated isolated and characterized. They belong to two from other species, except for the presence of an structually related classes, namely those related to extra four amino acids at the N-terminus. The adrenocorticotrophin (ACTH) including ACTH, presence of sufficient amounts of 8-MSH in human a-melanocyte-stimulating hormone (a-MSH) and pituitaries to account alone for the bulk of the 'corticotrophin-like intermediate lobepeptide' ACTH melanocyte-stimulating activity in the pituitary (18-39) peptide (CLIP), and others related to fi- extracts was shown by radioimmunoassay (Abe et al., melanocyte-stimulating hormone (,B-MSH) including 1967b). -
The Hypothalamus and the Regulation of Energy Homeostasis: Lifting the Lid on a Black Box
Proceedings of the Nutrition Society (2000), 59, 385–396 385 CAB59385Signalling39612© NutritionInternationalPNSProceedings Society in body-weight 2000 homeostasisG. of the Nutrition Williams Society et (2000)0029-6651©al.385 Nutrition Society 2000 593 The hypothalamus and the regulation of energy homeostasis: lifting the lid on a black box Gareth Williams*, Joanne A. Harrold and David J. Cutler Diabetes and Endocrinology Research Group, Department of Medicine, The University of Liverpool, Liverpool L69 3GA, UK Professor Gareth Williams, fax +44 (0)151 706 5797, email [email protected] The hypothalamus is the focus of many peripheral signals and neural pathways that control energy homeostasis and body weight. Emphasis has moved away from anatomical concepts of ‘feeding’ and ‘satiety’ centres to the specific neurotransmitters that modulate feeding behaviour and energy expenditure. We have chosen three examples to illustrate the physiological roles of hypothalamic neurotransmitters and their potential as targets for the development of new drugs to treat obesity and other nutritional disorders. Neuropeptide Y (NPY) is expressed by neurones of the hypothalamic arcuate nucleus (ARC) that project to important appetite-regulating nuclei, including the paraventricular nucleus (PVN). NPY injected into the PVN is the most potent central appetite stimulant known, and also inhibits thermogenesis; repeated administration rapidly induces obesity. The ARC NPY neurones are stimulated by starvation, probably mediated by falls in circulating leptin and insulin (which both inhibit these neurones), and contribute to the increased hunger in this and other conditions of energy deficit. They therefore act homeostatically to correct negative energy balance. ARC NPY neurones also mediate hyperphagia and obesity in the ob/ob and db/db mice and fa/fa rat, in which leptin inhibition is lost through mutations affecting leptin or its receptor. -
Expression and Localization of Gastrin Messenger RNA and Peptide in Spermatogenic Cells
Expression and localization of gastrin messenger RNA and peptide in spermatogenic cells. M Schalling, … , T Hökfelt, J F Rehfeld J Clin Invest. 1990;86(2):660-669. https://doi.org/10.1172/JCI114758. Research Article In previous studies we have shown that the gene encoding cholecystokinin (CCK) is expressed in spermatogenic cells of several mammalian species. In the present study we show that a gene homologous to the CCK-related hormone, gastrin, is expressed in the human testis. The mRNA hybridizing to a human gastrin cDNA probe in the human testis was of the same size (0.7 kb) as gastrin mRNA in the human antrum. By in situ hybridization the gastrinlike mRNA was localized to seminiferous tubules. Immunocytochemical staining of human testis revealed gastrinlike peptides in the seminiferous tubules primarily at a position corresponding to spermatids and spermatozoa. In ejaculated spermatozoa gastrinlike immunoreactivity was localized to the acrosome. Acrosomal localization could also be shown in spermatids with electron microscopy. Extracts of the human testis contained significant amounts of progastrin, but no bioactive amidated gastrins. In contrast, ejaculated sperm contained mature carboxyamidated gastrin 34 and gastrin 17. The concentration of gastrin in ejaculated human spermatozoa varied considerably between individuals. We suggest that amidated gastrin (in humans) and CCK (in other mammals) are released during the acrosome reaction and that they may be important for fertilization. Find the latest version: https://jci.me/114758/pdf Expression and Localization of Gastrin Messenger RNA and Peptide in Spermatogenic Cells Martin Schalling,* Hhkan Persson,t Markku Pelto-Huikko,*9 Lars Odum,1I Peter Ekman,I Christer Gottlieb,** Tomas Hokfelt,* and Jens F. -
Activation of Orexin System Facilitates Anesthesia Emergence and Pain Control
Activation of orexin system facilitates anesthesia emergence and pain control Wei Zhoua,1, Kevin Cheunga, Steven Kyua, Lynn Wangb, Zhonghui Guana, Philip A. Kuriena, Philip E. Bicklera, and Lily Y. Janb,c,1 aDepartment of Anesthesia and Perioperative Care, University of California, San Francisco, CA 94143; bDepartment of Physiology, University of California, San Francisco, CA 94158; and cHoward Hughes Medical Institute, University of California, San Francisco, CA 94158 Contributed by Lily Y. Jan, September 10, 2018 (sent for review May 22, 2018; reviewed by Joseph F. Cotten, Beverley A. Orser, Ken Solt, and Jun-Ming Zhang) Orexin (also known as hypocretin) neurons in the hypothalamus Orexin neurons may play a role in the process of general an- play an essential role in sleep–wake control, feeding, reward, and esthesia, especially during the recovery phase and the transition energy homeostasis. The likelihood of anesthesia and sleep shar- to wakefulness. With intracerebroventricular (ICV) injection or ing common pathways notwithstanding, it is important to under- direct microinjection of orexin into certain brain regions, pre- stand the processes underlying emergence from anesthesia. In this vious studies have shown that local infusion of orexin can shorten study, we investigated the role of the orexin system in anesthe- the emergence time from i.v. or inhalational anesthesia (19–23). sia emergence, by specifically activating orexin neurons utilizing In addition, the orexin system is involved in regulating upper the designer receptors exclusively activated by designer drugs airway patency, autonomic tone, and gastroenteric motility (24). (DREADD) chemogenetic approach. With injection of adeno- Orexin-deficient animals show attenuated hypercapnia-induced associated virus into the orexin-Cre transgenic mouse brain, we ventilator response and frequent sleep apnea (25). -
Orexin Reverses Cholecystokinin-Induced Reduction in Feeding
ORIGINAL ARTICLE Orexin reverses cholecystokinin-induced reduction in feeding A. Asakawa,1 A. Inui,1 T. Inui,2 G. Katsuura,3 M. A. Fujino4 and M. Kasuga1 1Division of Diabetes, Digestive and Kidney Diseases, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan 2Inui Clinic, Osaka, Japan 3Shionogi Research Laboratories, Shionogi & Co Ltd, Shiga, Japan 4First Department of Internal Medicine, Yamanashi Medical University, Yamanashi, Japan Aim: This study was designed to investigate the effect of orexin on anorexia induced by cholecystokinin (CCK), a peripheral satiety signal. Methods: We administered orexin A (0.01±1 nmol/mouse) and CCK-8 (3 nmol/mouse) to mice. Food intake was measured at different time-points: 20 min, 1, 2 and 4 h post-intracerebroventricular (i.c.v.) or intraperitoneal (i.p.) administrations. Results: Intracerebroventricular-administered orexin significantly increased food intake in a dose-dependent man- ner. The inhibitory effect of i.p.-administered CCK-8 on food intake was significantly negated by the simultaneous i.c.v. injection of orexin in a dose-dependent manner. Conclusions: Orexin reversed the CCK-induced loss of appetite. Our results indicate that orexin might be a promising target for pharmacological intervention in the treatment of anorexia and cachexia induced by various diseases. Keywords: orexin, cholecystokinin, mice, food intake, anorexia Received 28 March 2002; returned for revision 20 May 2002; revised version accepted 21 June 2002 Introduction However, the relationship between orexin and per- ipheral satiety systems still remains to be determined. Orexin is a hypothalamic neuropeptide identified as a We investigated the effect of orexin on anorexia induced ligand for an orphan G-protein coupled receptor [1±3]. -
Supplementary Table 1. Clinico-Pathologic Features of Patients with Pancreatic Neuroendocrine Tumors Associated with Cushing’S Syndrome
Supplementary Table 1. Clinico-pathologic features of patients with pancreatic neuroendocrine tumors associated with Cushing’s syndrome. Review of the English/Spanish literature. Other hormones Age of Cortisol Other hormones Other ACTH Size (ICH or assay) ENETS Follow- Time Year Author Sex CS onset level (Blood syndromes or Site MET Type AH level (cm) corticotrophic Stage up (months) (years) (µg/dl) detection) NF other differentiation 1 1 1946 Crooke F 28 uk uk none no 4.5 H liver/peritoneum NET uk uk yes IV DOD 6 2 1956 Rosenberg 2 F 40 uk 92 none no 10 B liver NET uk uk yes IV PD 3 & p 3 1959 Balls F 36 uk elevated insulin Insulinoma 20 B liver/LNl/lung NET uk uk yes IV DOD 1 4 & 4 1962 Meador F 47 13~ elevated none no uk T liver/spleen NET ACTH uk yes IV uk 5 1963 Liddle5 uk uk uk elevated uk uk uk uk uk NET ACTH uk uk uk uk 6 1964 Hallwright6 F 32 uk uk none no large H LN/liver NET ACTH, MSH uk yes IV DOD 24 7 1965 Marks7 M 43 uk elevated insulin insulinomas 1.8 T liver NET uk uk yes IV DOD 7 8 1965 Sayle8 F 62 uk uk none carcinoidb 4 H LN/liver NET uk uk yes IV DOD 6 9 1965 Sayle8 F 15 uk uk none no 4 T no NET ACTH uk yes IIa DOD 5 9 b mesentery/ 10 1965 Geokas M 59 uk uk gastrin ZES large T NET uk uk yes IV DOD 2 LN/pleural/bone 11 1965 Law10 F 35 1.2 ∞ 91 gastrin ZESs uk B LN/liver NET ACTH, MSH gastrin yes IV PD 12 1967 Burkinshaw11 M 2 uk 72 none no large T no NET uk uk no uk AFD 12 13 1968 Uei12 F 9 uk uk none ZESs 7 T liver NET ACTH uk yes IV DOD 8 13 PTH, ADH, b gastrin, 14 1968 O'Neal F 52 13~ uk ZES uk T LN/liver/bone NET -
Effect of Atropine on Vagal Release of Gastrin and Pancreatic Polypeptide
Effect of Atropine on Vagal Release of Gastrin and Pancreatic Polypeptide MARK FELDMAN, CHARLES T. RICHARDSON, IAN L. TAYLOR, and JOHN H. WALSH, Departments of Internal Medicine, Veterans Administration Hospital, Dallas, Texas 75216; University of California at Los Angeles Health Science Center, Los Angeles, California 90093; and The University of Texas Health Science Center at Dallas, Southwestern Medical School, Dallas, Texas 75235 A B S TRA C T We studied the effect of several doses of the rise in serum gastrin concentration induced by in- atropine on the serum gastrin and pancreatic poly- sulin hypoglycemia was further increased by atropine peptide responses to vagal stimulation in healthy premedication (1). In addition, several workers have human subjects. Vagal stimulation was induced by shown that atropine increases the serum gastrin con- sham feeding. To eliminate the effect of gastric acidity centration after an eaten meal (2-4). These observa- on gastrin release, gastric pH was held constant (pH 5) tions, together with the fact that basal and postprandial and acid secretion was measured by intragastric titra- gastrin levels rise after vagotomy (5-7), have led to tion. Although a small dose of atropine (2.3 ,ug/kg) speculation that the vagus nerve can inhibit, as well as significantly inhibited the acid secretory response and stimulate, gastrin release. completely abolished the pancreatic polypeptide re- For several reasons, however, none of these observa- sponse to sham feeding, this dose of atropine signifi- tions proves that the vagus nerve actually inhibits cantly enhanced the gastrin response. Higher atropine gastrin release under normal circumstances. First, doses (7.0 and 21.0,g/kg) had effects on gastrin and studies using insulin hypoglycemia as a vagal stimulant pancreatic polypeptide release which were similar to must be interpreted with caution because there is the 2.3-pAg/kg dose. -
Neuropeptides Controlling Energy Balance: Orexins and Neuromedins
Neuropeptides Controlling Energy Balance: Orexins and Neuromedins Joshua P. Nixon, Catherine M. Kotz, Colleen M. Novak, Charles J. Billington, and Jennifer A. Teske Contents 1 Brain Orexins and Energy Balance ....................................................... 79 1.1 Orexin............................................................................... 79 2 Orexin and Feeding ....................................................................... 80 3 Orexin and Arousal ....................................................................... 83 J.P. Nixon • J.A. Teske Veterans Affairs Medical Center, Research Service (151), Minneapolis, MN, USA Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA Minnesota Obesity Center, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA C.M. Kotz (*) Veterans Affairs Medical Center, GRECC (11 G), Minneapolis, MN, USA Veterans Affairs Medical Center, Research Service (151), Minneapolis, MN, USA Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA Minnesota Obesity Center, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA e-mail: [email protected] C.M. Novak Department of Biological Sciences, Kent State University, Kent, OH, USA C.J. Billington Veterans Affairs Medical Center, Research Service (151), Minneapolis, MN, USA Veterans Affairs Medical Center, Endocrine Unit (111 G), Minneapolis, MN, USA Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA Minnesota Obesity Center, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108, USA H.-G. Joost (ed.), Appetite Control, Handbook of Experimental Pharmacology 209, 77 DOI 10.1007/978-3-642-24716-3_4, # Springer-Verlag Berlin Heidelberg 2012 78 J.P. Nixon et al. 4 Orexin Actions on Endocrine and Autonomic Systems ................................. 84 5 Orexin, Physical Activity, and Energy Expenditure .................................... -
Calcitonin Gene-Related Peptide Facilitates Sensitization of The
Zhang et al. The Journal of Headache and Pain (2020) 21:72 The Journal of Headache https://doi.org/10.1186/s10194-020-01145-y and Pain RESEARCH ARTICLE Open Access Calcitonin gene-related peptide facilitates sensitization of the vestibular nucleus in a rat model of chronic migraine Yun Zhang1, Yixin Zhang1*, Ke Tian2, Yunfeng Wang1, Xiaoping Fan1, Qi Pan1, Guangcheng Qin3, Dunke Zhang3, Lixue Chen2 and Jiying Zhou1 Abstract Background: Vestibular migraine has recently been recognized as a novel subtype of migraine. However, the mechanism that relate vestibular symptoms to migraine had not been well elucidated. Thus, the present study investigated vestibular dysfunction in a rat model of chronic migraine (CM), and to dissect potential mechanisms between migraine and vertigo. Methods: Rats subjected to recurrent intermittent administration of nitroglycerin (NTG) were used as the CM model. Migraine- and vestibular-related behaviors were analyzed. Immunofluorescent analyses and quantitative real- time polymerase chain reaction were employed to detect expressions of c-fos and calcitonin gene-related peptide (CGRP) in the trigeminal nucleus caudalis (TNC) and vestibular nucleus (VN). Morphological changes of vestibular afferent terminals was determined under transmission electron microscopy. FluoroGold (FG) and CTB-555 were selected as retrograde tracers and injected into the VN and TNC, respectively. Lentiviral vectors comprising CGRP short hairpin RNA (LV-CGRP) was injected into the trigeminal ganglion. Results: CM led to persistent thermal hyperalgesia, spontaneous facial pain, and prominent vestibular dysfunction, accompanied by the upregulation of c-fos labeling neurons and CGRP immunoreactivity in the TNC (c-fos: vehicle vs. CM = 2.9 ± 0.6 vs. -
Significance of the Orexinergic System in Modulating Stress-Related
Cohen et al. Translational Psychiatry (2020) 10:10 https://doi.org/10.1038/s41398-020-0698-9 Translational Psychiatry ARTICLE Open Access Significance of the orexinergic system in modulating stress-related responses in an animal model of post-traumatic stress disorder Shlomi Cohen1,2,MichaelA.Matar1, Ella Vainer1, Joseph Zohar3,4,ZeevKaplan1 and Hagit Cohen1,2 Abstract Converging evidence indicates that orexins (ORXs), the regulatory neuropeptides, are implicated in anxiety- and depression-related behaviors via the modulation of neuroendocrine, serotonergic, and noradrenergic systems. This study evaluated the role of the orexinergic system in stress-associated physiological responses in a controlled prospective animal model. The pattern and time course of activation of hypothalamic ORX neurons in response to predator-scent stress (PSS) were examined using c-Fos as a marker for neuronal activity. The relationship between the behavioral response pattern 7 days post-exposure and expressions of ORXs was evaluated. We also investigated the effects of intracerebroventricular microinfusion of ORX-A or almorexant (ORX-A/B receptor antagonist) on behavioral responses 7 days following PSS exposure. Hypothalamic levels of ORX-A, neuropeptide Y (NPY), and brain-derived neurotrophic factor (BDNF) were assessed. Compared with rats whose behaviors were extremely disrupted (post- traumatic stress disorder [PTSD]-phenotype), those whose behaviors were minimally selectively disrupted displayed significantly upregulated ORX-A and ORX-B levels in the hypothalamic nuclei. Intracerebroventricular microinfusion of ORX-A before PSS reduced the prevalence of the PTSD phenotype compared with that of artificial cerebrospinal fluid or almorexant, and rats treated with almorexant displayed a higher prevalence of the PTSD phenotype than did 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; untreated rats. -
Non-Commercial Use Only
Translational Medicine Reports 2019; volume 3:8142 Antibacterial and antiviral precursor, prepro-orexin, that is then potential of neuropeptides cleaved to generate the active molecules.10- Correspondence: Gianluigi Franci, 12 Orexin-A is a 33 amino acids peptide Department of Experimental Medicine, including 4 cysteines linked by two intra- University of Campania Luigi Vanvitelli, Carla Zannella, Debora Stelitano, chain disulfide bonds.13,14 Post-translational Via Costantinopoli 16, 80138 Naples, Italy. E-mail: [email protected] Veronica Folliero, Luciana Palomba, modifications of this peptide include a Tiziana Francesca Bovier, Roberta pyroglutamyl cyclization at the N-terminal Key words: Antibacterial; Antiviral; Astorri, Annalisa Chianese, and a C-terminal amidation. Orexin-B is a Neuropeptides; Orexins; Ghrelin. Marcellino Monda, Marilena Galdiero, 28 residue neuropeptide and like orexin-A Gianluigi Franci is characterized by a C-terminal amida- Contributions: CZ and DS contributed equal- 10,14 ly; VF, LP, TFB, RA, AC, MM, MG, data col- Department of Experimental Medicine, tion. The two neuropeptides share 46% 10 lecting and manuscript reviewing and refer- University of Campania Luigi Vanvitelli, of sequence homology. Two-dimensional NMR spectroscopy analysis of soluble ence search; GF, data collecting, figures Naples, Italy preparation and manuscript writing. orexin-B revealed that its structure consists 10 of two α–helices linked via a flexible loop. Conflict of interest: the authors declare no The lateral hypothalamus, where the neu- potential conflict of interest. Abstract ropeptides are generated, is responsible for eating behavior and energy homeosta- Funding: VALEREplus Program. The emergence of multidrug resistant sis.6,15,16 Indeed, orexins play a key role in bacteria is a global health threat and the dis- feeding behavior and body weight regula- Received for publication: 28 February 2019.